$16.53
0.73% yesterday
Nasdaq, Dec 23, 10:01 pm CET
ISIN
US64049M2098
Symbol
NEO

NeoGenomics, Inc. Stock price

$16.53
-0.40 2.36% 1M
+3.36 25.51% 6M
+0.35 2.16% YTD
-4.20 20.26% 1Y
-17.80 51.85% 3Y
-13.31 44.60% 5Y
+12.40 300.24% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
+0.12 0.73%
ISIN
US64049M2098
Symbol
NEO
Sector

Key metrics

Market capitalization $2.12b
Enterprise Value $2.34b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.63
P/S ratio (TTM) P/S ratio 3.29
P/B ratio (TTM) P/B ratio 2.33
Revenue growth (TTM) Revenue growth 12.06%
Revenue (TTM) Revenue $644.12m
EBIT (operating result TTM) EBIT $-86.12m
Free Cash Flow (TTM) Free Cash Flow $-21.51m
Cash position $387.81m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 3.21
EV/Sales forward 3.54
Short interest 3.99%
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
73%
Hold
27%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
644 644
12% 12%
100%
- Direct Costs 383 383
7% 7%
59%
261 261
20% 20%
41%
- Selling and Administrative Expenses 244 244
13% 13%
38%
- Research and Development Expense 30 30
13% 13%
5%
-13 -13
46% 46%
-2%
- Depreciation and Amortization 73 73
8% 8%
11%
EBIT (Operating Income) EBIT -86 -86
17% 17%
-13%
Net Profit -78 -78
19% 19%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Neutral
Business Wire
13 days ago
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.
Neutral
Business Wire
15 days ago
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH.
Neutral
Business Wire
19 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collabo...
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Chris Smith
Employees 2,100
Founded 1998
Website www.neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today